Expression of autotaxin and acylglycerol kinase in prostate cancer: Association with cancer development and progression

Cancer Science

Volumn 100, Issue 9, 2009, Pages 1631-1638

  Nouh, Mohammed Ahmed Abdel Muneem ^a,b   Wu, Xiu Xian ^a   Okazoe, Homare ^a   Tsunemori, Hiroyuki ^a   Haba, Reiji ^a   Abou Zeid, Abdel Muneem Mohammed ^b   Saleem, Mohammed Diaa ^b   Inui, Masashi ^a   Sugimoto, Mikio ^a   Aoki, Junken ^c   Kakehi, Yoshiyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Sohag University   (Egypt)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGK PROTEIN, HUMAN; ENPP2 PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; MESSENGER RNA; MULTIENZYME COMPLEX; PHOSPHODIESTERASE I; PHOSPHOTRANSFERASE;

AGED; ARTICLE; CELL CULTURE; DISEASE COURSE; ENZYME IMMUNOASSAY; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

AGED; CELLS, CULTURED; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; PHOSPHODIESTERASE I; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PYROPHOSPHATASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 70149121909     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01234.x     Document Type: Article

References (31)

1. Bektas M, Payne S, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 2005; 169: 801-11.
2. Yamada T, Yano S, Ogino H et al. Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2. Cancer Sci 2008; 99:1603-10.
3. Imamura F, Mukai M, Ayaki M, Akedo H. 3Y-27632, an Inhibitor of Rhoassociated Protein Kinase, Suppresses Tumor Cell Invasion via Regulation of Focal Adhesion and Focal Adhesion Kinase. Jpn J Cancer Res 2000; 91: 811-6.
4. Meyer zu Heringdorf D, Jacobs KH. Lysophospholipid receptors: signaling,pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 2007; 1768: 923-40.
5. Karin M, Cao Y, Greten FR, Li ZW. NF-kappa B in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10.
6. Prenzel N, Zwick E, Daub H et al. EGF receptor transactivation by Gprotein-coupled receptors requires metalloproteinase cleavage of pro HB-EGF. Nature 1999; 402: 884-8.
7. Daaka Y. Mitogenic action of LPA in prostate. Biochim Biophys Acta 2002;1582: 265-9.
8. Goetzl EJ, Kong Y, Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 1999; 162: 2049-56.
9. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, Serban M.Phosphatase-resistant analogues of lysophosphatidic acid: Agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 2008; 1781: 588-94.
10. Hama K, Bandoh K, Kakehi Y, Aokia J, Araia H. Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett 2002;523: 187-92.
11. Sakamoto S, Yokoyama M, Zhang X et al. Increased expression of CYR61,an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology 2004;145: 2929-40.
12. Siess W, Zangl KJ, Essler M et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA 1999; 96: 6931-6.
13. Sano T, Baker D, Virag T et al. Multiple mechanisms linked to platelet activation result in Lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 2002; 277: 21197-206.
14. Budnik LT, Mukhopadhyay AK. Lysophosphatidic acid and its role in reproduction: Minireview. Biol Reprod 2002; 66: 859-65.
15. Tokumura A, Majima E, Kariya Y et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin,a multifunctional phosphodiesterase. J Biol Chem 2002; 277: 39436-42.
16. Kishi Y, Okudaira S, Tanaka M et al. Autotaxin is over expressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006; 281: 17492-500.
17. Gendaszewska-Darmach E. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases. Acta Biochim Pol 2008; 55: 227-40.
18. Umezu-Goto M, Kishi Y, Taira A et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158: 227-33.
19. van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007; 46: 145-60.
20. Kulkarni P, Getzenberg RH. High-fat diet, obesity and prostate disease: the ATX-LPA axis? Nat Clin Pract Urol 2009; 6: 128-31.
21. Spiegel S, Milstien S. Critical role of acylglycerol kinase in epidermal growth factor-induced mitogenesis of prostate cancer cells. Biochem Soc Trans 2005; 33: 1362-5.
22. Tanaka M, Kishi Y, Takanezawa Y, Kakehi Y, Aoki J, Arai H. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett 2004; 571: 197-204.
23. Inoue T, Yoshida T, Shimizu Y et al. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells. Mol Endocrinol 2006; 12: 3053-69.
24. Takagi H, Shibutani M, Kato N et al. Microdissected region-specific gene expression analysis with methacarn-fixed, paraffin-embedded tissues by real-time RT-PCR. J Histochem Cytochem 2004; 52: 903-13.
25. Wu X, Kakehi Y, Zeng Y, Taoka R, Tsunemori H, Inui M. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol 2005; 174: 2138-42.
26. Tickoo SK, Alden D, Olgac S et al. Immunohistochemical expression of hypoxia inducible factor-1α and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol 2007; 177: 1258-63.
27. Clarke NW. What does failure after surgery or radiation mean? Eur Urol Suppl 2008; 7: 410-5.
28. Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, Wu XX. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: Relevance to prostate cancer and benign hyperplasia. Prostate 2009; 69: 283-92.
29. Seifert A, Klonisch T, Wulfaenger J et al. The cellular localization of autotaxin impacts on its biological functions in human thyroid carcinoma cells. Oncol Rep 2008; 19: 1485-91.
30. van Meeteren LA, Ruurs P, Christodoulou E et al. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 2005; 280:21155-61.
31. Nakamura K, Takeuchi T, Ohkawa R et al. Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker: study on prostate cancer patients. Ann Clin Biochem 2007; 44: 549-56.